Skip to main content

Interactions between Infanate DHA and Odevixibat

1 drug interaction and 6 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

multivitamins, prenatal odevixibat

Applies to: Infanate DHA (multivitamin, prenatal) and odevixibat
Monitor

Odevixibat may affect absorption of fat-soluble vitamins (FSV) including vitamin A, D, E, and K. In clinical studies, new onset or worsening of existing FSV deficiency was reported in 5% of placebo-treated patients, and in 16% of odevixibat-treated 120 mcg/kg/day patients. However, none of the odevixibat-treated 40 mcg/kg/day patients had new onset or worsening of existing FSV deficiency.

Management

Clinical and laboratory monitoring of FSV levels is recommended prior to and during treatment with odevixibat. Monitor INR (for vitamin K) and serum vitamins A, D, and E, and supplement if a deficiency is observed. Odevixibat should be discontinued if FSV deficiency persists or worsens, or if bleeding occurs despite adequate FSV supplementation.

References (4)
  1. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Pty Ltd
  2. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Ltd
  3. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Biopharmaceuticals, Inc
  4. (2025) "Product Information. Bylvay (odevixibat)." Medison Pharma Canada Inc

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

multivitamins, prenatal Food/Lifestyle

Applies to: Infanate DHA (multivitamin, prenatal)
Adjust dosing interval

Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa. Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

Management

Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References (2)
  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
Moderate:

odevixibat Food/Lifestyle

Applies to: odevixibat
Monitor

Odevixibat may affect absorption of fat-soluble vitamins (FSV) including vitamin A, D, E, and K. In clinical studies, new onset or worsening of existing FSV deficiency was reported in 5% of placebo-treated patients, and in 16% of odevixibat-treated 120 mcg/kg/day patients. However, none of the odevixibat-treated 40 mcg/kg/day patients had new onset or worsening of existing FSV deficiency.

Management

Clinical and laboratory monitoring of FSV levels is recommended prior to and during treatment with odevixibat. Monitor INR (for vitamin K) and serum vitamins A, D, and E, and supplement if a deficiency is observed. Odevixibat should be discontinued if FSV deficiency persists or worsens, or if bleeding occurs despite adequate FSV supplementation.

References (4)
  1. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Pty Ltd
  2. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Ltd
  3. (2025) "Product Information. Bylvay (odevixibat)." Ipsen Biopharmaceuticals, Inc
  4. (2025) "Product Information. Bylvay (odevixibat)." Medison Pharma Canada Inc

Disease interactions

4 potential interactions Applies to: 4 conditions, including Vitamin D Deficiency, Vitamin A Deficiency, Vitamin K Deficiency, and Cirrhosis.

Cirrhosis

Major:

odevixibat

Odevixibat has a major potential interaction with Cirrhosis.

Ileal bile acid transporters, including odevixibat, are contraindicated in patients with prior or active hepatic decompensation events. The efficacy and safety of odevixibat in patients with clinically significant portal hypertension and in patients with decompensated cirrhosis have not been established. Monitor these patients more frequently and discontinue treatment if hepatic decompensation occurs.

Vitamin A Deficiency

Moderate:

odevixibat

Odevixibat has a moderate potential interaction with Vitamin A Deficiency.

Odevixibat may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamin A, D, E, and K (measured using INR levels). Patients with progressive familial intrahepatic cholestasis and arteriohepatic dysplasia can have FSV deficiency at baseline and frequently need supplementing with FSV.

Vitamin D Deficiency

Moderate:

odevixibat

Odevixibat has a moderate potential interaction with Vitamin D Deficiency.

Odevixibat may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamin A, D, E, and K (measured using INR levels). Patients with progressive familial intrahepatic cholestasis and arteriohepatic dysplasia can have FSV deficiency at baseline and frequently need supplementing with FSV.

Vitamin K Deficiency

Moderate:

odevixibat

Odevixibat has a moderate potential interaction with Vitamin K Deficiency.

Odevixibat may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamin A, D, E, and K (measured using INR levels). Patients with progressive familial intrahepatic cholestasis and arteriohepatic dysplasia can have FSV deficiency at baseline and frequently need supplementing with FSV.

Report options

Loading...
QR code containing a link to this page

More resources

Infanate DHA

A total of 172 drugs are known to interact with Infanate DHA.

odevixibat

A total of 65 drugs are known to interact with odevixibat.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer